ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Diagnostic value of 24-h urinary aldosterone and related biomarkers for screening primary aldosteronism in medication-exposed populations
Provisionally accepted
- Beijing Anzhen Hospital, Capital Medical University, Chaoyang District, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the screening value of 24-hour urinary aldosterone (24h-Uald) and the urinary aldosterone–to–renin ratio (UARR) for primary aldosteronism (PA in hypertensive patients under conditions of ongoing antihypertensive medication use. Methods: Hypertensive patients who underwent PA screening at our hospital between August 2024 and August 2025 were retrospectively enrolled. Baseline clinical characteristics and biochemical parameters were collected while patients were receiving ongoing antihypertensive therapy. Multivariable logistic regression analysis was performed to assess the independent associations of 24h-Uald and UARR with PA. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Both 24h-Uald and UARR levels were significantly higher in patients with PA than in those with essential hypertension (EH) (P < 0.05). After adjustment for potential confounders, including age, body mass index, renal function, and history of coronary artery disease, 24h-Uald and UARR remained independently associated with PA. ROC curve analysis demonstrated a modest diagnostic performance for 24h-Uald (AUC = 0.657), whereas UARR exhibited excellent diagnostic accuracy (AUC = 0.862). Conclusions: Under conditions of ongoing antihypertensive medication use, the diagnostic performance of 24h-Uald alone for PA screening is limited. In contrast, UARR, incorporating renin measurements, demonstrates higher diagnostic accuracy and greater clinical utility.
Keywords: Aldosterone-to-renin ratio, Hypertension, medication effect, primary aldosteronism, Urinary aldosterone
Received: 20 Jan 2026; Accepted: 16 Feb 2026.
Copyright: © 2026 Chen, Chen, Wu, Yang, Shen and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hui Yuan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.